Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
The science on this is still developing, but the early evidence is consistent, and the patient experience is compelling
[7] [8] Should you have any concerns about a missed dose, contact your GP or diabetes specialist nurse for personalised advice
This flexibility represents an important practical advantage, allowing patients to choose a schedule that best fits their lifestyle and daily routine
The Science Behind GLP1 Receptor Agonists Managing weight is key for people with Prader-Willi Syndrome (PWS)
The accumulation of AGEs in the body irreversibly modifies the structure and function of proteins such as collagen and elastin